Mammoth Biosciences, Inc.

Presentation to take place at 7.30 am PT on Thursday, January 15, 2026 BRISBANE, Calif.--(BUSINESS WIRE)-- #CRISPR -- Mammoth Biosciences, Inc. , a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing platform to create potential one-time curative therapies, today announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference. Trevor Martin, Ph.D., co-founder and CEO, will provide a corporate overview with key business updates related to Mammoth Biosciences' pipeline and platform on Thursday, January 15 at 7.30 am PT in San Francisco. About Mammoth Biosciences Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact systems are designed to be more specific and packageable to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, reverse transcriptase editing, and epigenetic editing. The company is building out its wholly owned pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology platform. Mammoth Biosciences’ deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the promise of CRISPR technologies. For more information, please visit or follow Mammoth on LinkedIn or X . Contacts Media Contact: Mohana Ray Email: Mammoth.PR@hdmz.com Phone: 312-506-5210

Regeneron Pharmaceuticals is expanding its investment in gene editing through a new partnership with Tessera Therapeutics, a well-funded startup that is preparing to test its first experimental therapy in a clinical trial. The therapy, which is based on Tessera’s gene writing technology , is designed to fix a genetic typo responsible for alpha-1 antitrypsin deficiency (AATD), a liver and lung disease that several biotech companies are racing to treat. Tessera will get $150 million, including in upfront cash and an equity investment, from Regeneron to co-develop the treatment. Regeneron was one of the first major drug developers to invest in gene editing through its collaboration with the CRISPR company Intellia Therapeutics back in 2016, which it expanded in 2023. Regeneron also partnered with the CRISPR company Mammoth Biosciences last year. Tessera was founded by Flagship Pioneering in 2018 and has raised at least $580 million from private investors as of May 2024. Since then, the Somerville, MA-based startup has announced up to $50 million in funding from the Gates Foundation and up to $41.3 million from an ARPA-H award from the US government for its in vivo cell therapy programs. The new money from Regeneron could push Tessera’s total funding north of $800 million. It comes amidst a prolonged downturn for the gene editing field. Many companies, including Tessera , have reduced their headcount this year as investors have increasingly turned away from gene editing. Yet Regeneron’s interest in Tessera shows that some bigger drugmakers still believe in the curative potential of CRISPR and related technologies. Eli Lilly acquired the base editing company Verve Therapeutics this summer and Chiesi Group partnered with the CRISPR company Arbor Biotechnologies in October. Tessera hasn’t said whether its gene writing technology relies on the same class of enzymes that power CRISPR gene editing. But details revealed during the company’s presentations at scientific conferences suggest a similarity to prime editing, a version of CRISPR that can add, delete or replace nearly any short stretch of DNA. Prime Medicine, which is developing therapies based on prime editing, is also working on a treatment for AATD. And CRISPR Therapeutics recently unveiled its twist on prime editing with plans to test it in an AATD clinical trial next year. Companies developing other technologies that can fix genetic typos, including RNA editing and base editing , are also racing to test their medicines in AATD. The disease is quickly becoming one of the most competitive arenas in the genetic medicine field because several aspects of the condition make it an ideal testing ground. AATD affects about 200,000 people in the US and Europe, making it one of the more common genetic conditions. Unlike most genetic diseases, it is largely caused by a single mutation, meaning one therapy could help most patients. And editing cells in the liver — where proven delivery technologies can more readily reach — may fix enough of the broken AAT enzyme to manage both liver and lung manifestations of the disease. Tessera previously said that it will start testing its AATD therapy, dubbed TSRA-196, in December. The Phase 1/2 trial could enroll 72 patients. It is unclear where the first patients will be dosed, but they will likely be outside the US, as Tessera said on Monday that it still plans to ask the US FDA for permission to start a trial by the end of the year. Tessera will lead the upcoming clinical trial, and Regeneron will lead further development and potential commercialization. The companies will split development costs and potential profits, and Tessera could get another $125 million in near and mid-term milestone payments.

Regeneron Pharmaceuticals is putting more money into gene editing, announcing Monday a partnership with Tessera Therapeutics to develop an experimental program for a rare liver and lung disease.At the center of the deal is a treatment Tessera, a well-funded startup backed by Flagship Pioneering, is developing for alpha-1 antitrypsin deficiency. Regeneron is paying Tessera $150 million upfront, in the form of cash and an equity investment, to collaborate on the program and split future development costs and profits. Tessera could receive another $125 million in unspecified near and mid-term development milestone payments. Tessera will lead the initial first-in-human trial, with Regeneron taking the reins for future development and eventually commercialization.Alpha-1 antitrypsin deficiency, or AATD, is a rare genetic condition that can cause lung and liver disease, such as chronic obstructive pulmonary disease and cirrhosis. The disorder is typically caused by a mutation in a gene called SERPINA1 and that provides instructions for a protective protein known as alpha-1 antitrypsin, or AAT.Treatment options for AATD are limited, dont reverse existing damage and largely only affect the diseases impact on the lungs. As a result, the disease has become a top target among drugmakersin recent years. Several companies are pursuing a variety of technological approaches, from RNA editingto base editingand RNA interference. Somehave suffered clinicalsetbacks.Tesseras program, TSRA-196, is designed to precisely correct the underlying genetic mutation in AATDand durably restore production of the AAT protein through a one-time treatment. Its also an in vivo gene editing treatment that does its work inside the body, rather than via a laborious process that involves manipulating cells in a lab.Alpha-1 antitrypsin deficiency is a serious disease with limited treatment options today and is particularly well suited for Tesseras gene editing approach. Together with Tessera, we have an opportunity to pioneer new frontiers in genetic medicine and redefine what is possible for AATD patients, said George Yancopoulos, Regenerons chief scientific officer, in a statement.TSRA-196 is in early research, however.Tessera presented preclinical dataearlier this year and expects to ask U.S. regulators by the end of 2025 to begin human testing.Though Regeneron is best known for the eye drug Eylea, its made genetic medicine a focus in recent years. Deals involving companies like Intellia Therapeutics, ViGeneron,Decibel Therapeutics and Mammoth Bioscienceshave given the company a pipeline of gene therapy and gene editing medicines.One of those treatments, for a rare type of inherited hearing loss, could soon get to market.Tessera, meanwhile, is led by former AbbVie executive Michael Severinoand has raised more than half a billion dollars in private funding since its inception. '